10-Q: American Well Corporation Reports Third Quarter 2024 Results, Revenue Declines Slightly Amidst Strategic Transformation

American Well Corporation's third quarter 2024 results show a slight revenue decrease and a net loss, as the company continues its strategic transformation and platform migration.

Summary

• American Well Corporation reported a revenue of $61.0 million for the third quarter of 2024, a slight decrease from $61.9 million in the same period last year.
• The company experienced a net loss of $44.0 million for the quarter, compared to a net loss of $137.1 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, revenue was $183.4 million, down from $188.4 million in the same period of 2023.
• The net loss for the first nine months of 2024 was $168.1 million, a significant improvement from the $629.1 million loss in the same period of 2023, which included a large goodwill impairment.
• The company's platform subscription revenue decreased due to customer churn during the re-platforming process, but this was partially offset by growth in strategic accounts and other revenue streams.
• The company completed approximately 4.5 million virtual care visits in the first nine months of 2024, with 24% of those visits being performed by AMG providers.
• The company is focused on migrating clients to the Amwell Converge platform, with approximately 70% of visits in the third quarter of 2024 being conducted on the new platform.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in reducing losses and migrating to a new platform, revenue is down and the company is still operating at a loss. The strategic transformation and focus on government clients are positive, but the company faces significant risks and challenges.

Positives

• The net loss significantly improved compared to the same period last year, primarily due to a reduction in operating expenses and the absence of a goodwill impairment charge.
• The company is making progress in migrating clients to the Amwell Converge platform, with 70% of visits now on the new platform.
• The company has implemented cost-saving measures, leading to a reduction in operating expenses.
• The company is expanding its relationship with key strategic accounts.
• The company is seeing growth in other revenue streams, such as marketing revenue with strategic customers.

Negatives

• Platform subscription revenue decreased due to customer churn during the re-platforming process.
• The company experienced a slight decrease in overall revenue compared to the same period last year.
• The company continues to operate at a loss, although the loss has been significantly reduced.
• The company is still in the process of migrating all clients to the Amwell Converge platform.

Risks

• The company faces risks related to weak growth and increased volatility in the digital care market.
• The company has a history of losses and may not achieve profitability.
• The company may face challenges in adapting to rapid technological changes.
• The company relies on a limited number of significant clients, and the loss of their business could impact results.
• The company faces increased competition from existing and potential new participants in the healthcare industry.
• Changes in healthcare laws and regulations could impact the company's ability to operate.
• The company is subject to risks related to compliance with regulations concerning personally identifiable information and personal health information.
• Slower than expected growth in patient adoption of digital care and platform usage could impact results.
• The company may face challenges in growing its base of affiliated and non-affiliated providers.
• The company is subject to risks related to cybersecurity breaches and failure to comply with privacy regulations.
• The company's ability to complete strategic transformation initiatives and the impact of such initiatives is uncertain.
• The company's ability to maintain strategic relationships with third parties is critical to its success.
• The impact of seasonal viruses on the company's business and ability to forecast is a risk.
• The company's insurance may not fully cover all potential exposures.
• The continuation of the DHA relationship beyond July of 2025 with comparable financial terms is a risk.

Future Outlook

The company expects to see a reduction in its ongoing research and development expense run rate in the fourth quarter of 2024. The company believes that its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months. The company plans to incur additional strategic transformation costs in order to align its recurring cost structure with its current revenue profile.

Management Comments

• A major strategic focus for us in 2024 is the delivery of solutions to our government clients as well as our existing commercial clients.
• We are focused on the transformational steps necessary to re-accelerate growth during this period of transition.
• We also continue to focus on the migration of our remaining health plan and health system clients onto the Amwell Converge platform.

Industry Context

The company operates in the rapidly evolving digital healthcare market, which is experiencing both growth and volatility. The company's focus on hybrid care models and its Amwell Converge platform are aligned with industry trends towards integrated and scalable digital health solutions. The company faces competition from other telehealth providers and technology companies in the healthcare space.

Comparison to Industry Standards

• The company's revenue decline is not uncommon in the telehealth sector as companies adjust to post-pandemic demand and focus on long-term growth strategies.
• The reduction in net loss and operating expenses is a positive sign, indicating the company's efforts to improve financial performance.
• The migration to a new platform is a significant undertaking, and the company's progress in this area is comparable to other companies undergoing similar transitions.
• The company's focus on government clients is a strategic move that aligns with the growing demand for digital health solutions in the public sector.
• The company's adjusted EBITDA loss is consistent with other growth-stage companies in the technology sector that are investing in product development and market expansion.
• The company's cash position is relatively strong, providing a buffer for future investments and operations.

Management Changes

Related Party Transactions

• The company has related-party transactions with Cleveland Clinic and CCAW, JV LLC.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the reduced losses.
• Employees may be impacted by the strategic transformation initiatives and potential headcount reductions.
• Customers may experience changes as the company migrates to the new platform.
• Suppliers may be impacted by the company's cost-saving measures.
• Creditors may be concerned about the company's ongoing losses but reassured by its cash position.

Next Steps

• The company will continue to focus on migrating clients to the Amwell Converge platform.
• The company will continue to deliver solutions to government clients.
• The company will continue to implement strategic transformation initiatives to re-accelerate growth.
• The company will continue to evaluate potential actions and may incur additional strategic transformation costs in future periods.

Key Dates

Keywords

telehealth, digital health, virtual care, platform subscription, healthcare, Amwell Converge, strategic transformation, revenue, net loss, customer churn, enterprise software, AMG, Carepoint devices